Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Oxford University's work on precision cancer medicine has received a significant boost after Cancer Research UK announced that it would give the existing Cancer Research UK Oxford Centre Major Centre status and increase funding for research in the city.

Load More

Similar stories

Terumo completes acquisition of University of Oxford spinout OrganOx for a record $1.5bn

OrganOx, a pioneering Oxford University spinout transforming kidney and liver transplantation, has been fully acquired by Terumo Corporation, a global medical technology company headquartered in Tokyo, Japan, for US$1.5 billion, marking the largest exit in Oxford University’s spinout portfolio to date and the first in excess of £1bn.